According to Mayo Clinic researchers, senolytic medications are effective in boosting a key protein in the body that may protect older people against complications like ageing and a variety of diseases. These findings, which are published ineBioMedicinedemonstrate this in mice and human studies.
Senolytics were developed at Mayo Clinic and given once clear the bloodstream of senescent or "zombie" cells. These cells contribute to multiple diseases and negative aspects of aging. This study shows that the removal of senescent cells significantly increased the production of a protective protein called -Klotho [Updated, March 22, 2022].
"We demonstrate that there is an opportunity for an orally active, small-molecule approach to increase this beneficial protein, and to intensify the use of senolytic drugs," writes a Mayo Clinic internist and senior author.
Researchers first demonstrated that senescent cells decreased levels of -Klotho in three types of human cells: umbilical vein endothelial cells, kidney cells, and brain cells. These also demonstrated that using the senolyitics desatinib plus quercitin in three types of mice that -Klotho was increased. And then, after administering desatinib plus quercitin in clinical trials subjects with idiopathic pulmonary fibro
"We are also the first to investigate the potential impact of fat-resident senescent cells on the brain," says Kyi Zhu, a Mayo Clinic physiologist and biomedical engineer. "This may open another avenue to examine the effect of peripheral senescent cells on brain aging."
The protein -Klotho is crucial to maintaining good health as it tends to decrease with age, and it especially decreases in several diseases, including Alzheimer''s, diabetes, and kidney disease. Animal studies have shown that decreasing -Klotho in mice shortens life span and increasing -Klotho in mice by inserting a gene that causes its production increases life span by 30%.
Discovering ways to increase -Klotho in humans has been a major research goal, but this has been difficult because of its size and instability. Bringing it directly is problematic, as it would have to be administered into a vein instead of by mouth.
Several studies have shown that senolytics, which can be used orally, increase -Klotho in people with idiopathic pulmonary fibrosis, an autoimmune illness that causes severe breathing difficulties and death.
Correction:The article erroneously stated a-klotho, and this was corrected on March 22, 2022 to -Klotho.